Add Formweb to your mobile device
Approved Formulary
Search results for:
baclofen
baclofen
Brand names: Lioresal
| Form | Strength |
|---|---|
| TABLET, ORAL | 10 mg |
Display GABA-derivative Skeletal Muscle Relaxants Class:
122012
Medication comments:
| 2023 American Geriatrics Society Beers Criteria® for potentially inappropriate medication use in older adults. | |
|---|---|
| Medication: | baclofen (Lioresal) |
| Criteria 4: Potentially clinically important drug-drug interactions that should be avoided in older adults. (Table 5) | |
| Interacting drug(s) or class(es) | skeletal muscle relaxants ⇄ CNS-active agents |
| Risk Rationale | Increased risk of falls and of fracture with the concurrent use of ≥3 CNS-active agents (antiepileptics including gabapentinoids, antidepressants, antipsychotics, benzodiazepines, Nonbenzodiazepine benzodiazepine receptor agonist hypnotics, opioids, and skeletal muscle relaxants). |
| Recommendation | Avoid concurrent use of ≥3 CNS-active drugs Click for list; minimize the number of CNS-active drugs. |
| Quality of evidence: High, Strength of Recommendation: Strong | |
| Criteria 5: medications that should be avoided or have their dosage reduced with varying levels of kidney function in older adults. (Table 6) | |
| CrCl (mL/min) at which action is required | eGFR <60 |
| Rationale | Increased risk of encephalopathy requiring hospitalization in older adults with eGFR <60 mL/min or who require chronic dialysis. |
| Recommendation | Avoid baclofen in older adults with impaired kidney function (eGFR <60 mL/min). When baclofen cannot be avoided, use the lowest effective dose and monitor for signs of CNS toxicity, including altered mental status. |
| Quality of evidence: Moderate, Strength of Recommendation: Strong | |
Last updated: Sep. 18, 2025
- Black Box Warnings Intrathecal: Abrupt discontinuation